Johnson & Johnson (JNJ)
(Delayed Data from NYSE)
$158.56 USD
-2.08 (-1.29%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $158.55 -0.01 (-0.01%) 7:58 PM ET
4-Sell of 5 4
C Value F Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$158.56 USD
-2.08 (-1.29%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $158.55 -0.01 (-0.01%) 7:58 PM ET
4-Sell of 5 4
C Value F Growth D Momentum D VGM
Zacks News
Should You Invest in the iShares U.S. Healthcare ETF (IYH)?
by Zacks Equity Research
Sector ETF report for IYH
How Should You Play J&J (JNJ) Stock After Q2 Earnings Beat?
by Kinjel Shah
Though J&J (JNJ) beat estimates for both earnings and sales in the second quarter, a new investor should avoid buying the stock right now due to its legal troubles.
AbbVie (ABBV) Beats on Q2 Earnings & Sales, Ups '24 EPS View
by Zacks Equity Research
AbbVie's (ABBV) second-quarter earnings and sales beat estimates. Management hikes the EPS guidance on encouraging product sales for immunology drugs.
GSK Stock Before Q2 Earnings: To Buy or Not to Buy?
by Sundeep Ganoria
We expect GSK's specialty products like Arexvy, Cabenuva, Juluca, Dovato, Trelegy Ellipta and Shingrix to drive second-quarter sales performance.
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Time for Healthcare ETFs?
by Sanghamitra Saha
Compelling valuation, innovation in specific growth areas and an aging population as well as increasing healthcare spending are the tailwinds of the medical sector.
GSK Blenrep Combos for Multiple Myeloma Accepted for EU Review
by Zacks Equity Research
GSK announces the acceptance of its regulatory filing, seeking the approval of Blenrep combinations for the treatment of relapsed or refractory multiple myeloma, for review in the EU.
AbbVie (ABBV) Stock Before Q2 Earnings: To Buy or Not to Buy?
by Sundeep Ganoria
Investor focus will likely be on sales of AbbVie's (ABBV) blockbuster immunology drugs Rinvoq and Skyrizi when it reports second-quarter results.
Should You Invest in the Vanguard Health Care ETF (VHT)?
by Zacks Equity Research
Sector ETF report for VHT
Pharma Stock Roundup: JNJ, NVS Q2 Earnings, RHHBY's Positive Obesity Pill Data
by Kinjel Shah
J&J (JNJ) and Novartis (NVS) beat estimates for earnings and sales. Roche's (RHHBY) oral weight loss GLP-1 therapy achieves positive results in an early-stage study.
Company News for Jul 18, 2024
by Zacks Equity Research
Companies in The News Are: JNJ,SYF,CFG,FHN
J&J (JNJ) Q2 Earnings & Sales Top, EPS View Cut on M&A Costs
by Kinjel Shah
J&J (JNJ) beats estimates for second-quarter earnings and sales. It lowers earnings expectations for 2024 due to costs related to recent acquisitions.
ORIC Pharmaceuticals (ORIC) Up on Collaboration With Bayer & JNJ
by Zacks Equity Research
ORIC Pharmaceuticals (ORIC) teams up with Bayer and Johnson & Johnson for a phase I study on ORIC-944 in patients with metastatic prostate cancer. Its shares rise on the news.
Housing Starts Increased More Than Expected
by Zacks Equity Research
Housing Starts Increased More Than Expected
Pre-Markets Book Profits; Housing Starts, J&J Q2 Up
by Mark Vickery
Pre-market futures are down at this hour, but not apparently as a result of any new reports ahead of the bell.
Johnson & Johnson (JNJ) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Johnson & Johnson (JNJ) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Johnson & Johnson (JNJ) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 4.06% and 0.43%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Stock Market News for Jul 16, 2024
by Zacks Equity Research
U.S stocks closed higher on Monday, building on Friday???s rally, as investors increased their bets on the chances of Donald Trump winning the U.S. presidential election in November following a failed assassination attempt on the Republican nominee over the weekend.
Dow Closes at New High as Q2 Earnings Season Heats Up
by Mark Vickery
Earnings season only picks up steam in the weeks to come.
Q2 Earnings Parade Continues
by Zacks Equity Research
Q2 Earnings Parade Continues
J&J (JNJ) Stock Before Q2 Earnings: To Buy or Not to Buy?
by Kinjel Shah
J&J's (JNJ) Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Stelara. Surgical procedure recovery and new products are likely to have driven MedTech sales.
Pre-Markets Up as 1st Full Week of Q2 Earnings Begins
by Mark Vickery
Goldman Sachs (GS) and BlackRock (BLK) both beat on Q2 earnings this morning, and we're just getting started.
Legend Biotech (LEGN) Up 12% on Reports of Takeover Bid
by Zacks Equity Research
A third-party article suggests that Legend Biotech (LEGN) hired investment banking firm Centerview Partners to help its board review the takeover offer.
3 Key Earnings Reports to Watch Next Week
by Derek Lewis
With the 2024 Q2 earnings season kicking into a much higher gear next week, there are several reports investors should keep on their radars, including these three.
Unlocking Q2 Potential of Johnson & Johnson (JNJ): Exploring Wall Street Estimates for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of Johnson & Johnson (JNJ) for the quarter ended June 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.